{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:11:47Z","timestamp":1790208707216,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["633004"],"award-info":[{"award-number":["633004"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001102","name":"Cancer Council NSW","doi-asserted-by":"publisher","award":["RG 18-05"],"award-info":[{"award-number":["RG 18-05"]}],"id":[{"id":"10.13039\/501100001102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jid.2020.12.038","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T20:43:02Z","timestamp":1616791382000},"page":"2238-2249.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5518-6605","authenticated-orcid":false,"given":"Abdullah Al","family":"Emran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7499-7515","authenticated-orcid":false,"given":"Hsin-Yi","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8187-3297","authenticated-orcid":false,"given":"Dilini","family":"Gunatilake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3862-0048","authenticated-orcid":false,"given":"Stuart J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2019-671X","authenticated-orcid":false,"given":"Farzana","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6225-5525","authenticated-orcid":false,"given":"Shudong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3064-737X","authenticated-orcid":false,"given":"Peter","family":"Hersey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2651-9671","authenticated-orcid":false,"given":"Stuart J.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1086-3953","authenticated-orcid":false,"given":"Jessamy C.","family":"Tiffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2020.12.038_bib1","doi-asserted-by":"crossref","first-page":"8206","DOI":"10.18632\/oncotarget.23654","article-title":"Distinct histone modifications denote early stress-induced drug tolerance in cancer","volume":"9","author":"Al Emran","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jid.2020.12.038_bib2","doi-asserted-by":"crossref","first-page":"FSO372","DOI":"10.4155\/fsoa-2018-0115","article-title":"Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy","volume":"5","author":"Alqahtani","year":"2019","journal-title":"Future Sci OA"},{"key":"10.1016\/j.jid.2020.12.038_bib3","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nrd3674","article-title":"Epigenetic protein families: a new frontier for drug discovery","volume":"11","author":"Arrowsmith","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jid.2020.12.038_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13046-018-0704-8","article-title":"CDK9 inhibitors in acute myeloid leukemia","volume":"37","author":"Boffo","year":"2018","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.jid.2020.12.038_bib5","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMra1112635","article-title":"Targeting epigenetic readers in cancer","volume":"367","author":"Dawson","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2020.12.038_bib6","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jid.2020.12.038_bib7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.it.2019.02.004","article-title":"Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy","volume":"40","author":"Emran","year":"2019","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jid.2020.12.038_bib8","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/cam4.1978","article-title":"Magnolol induces cell death through PI3K\/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma","volume":"8","author":"Emran","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.jid.2020.12.038_bib9","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.3390\/cancers12082082","article-title":"Study of the female sex survival advantage in melanoma-A focus on X-linked epigenetic regulators and immune responses in two cohorts","volume":"12","author":"Emran","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jid.2020.12.038_bib10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nmeth.1906","article-title":"ChromHMM: automating chromatin-state discovery and characterization","volume":"9","author":"Ernst","year":"2012","journal-title":"Nat Methods"},{"key":"10.1016\/j.jid.2020.12.038_bib11","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.celrep.2017.03.078","article-title":"Systematic epigenomic analysis reveals chromatin states associated with melanoma progression","volume":"19","author":"Fiziev","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.jid.2020.12.038_bib12","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/ijc.31199","article-title":"HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma","volume":"142","author":"Gallagher","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jid.2020.12.038_bib13","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/pcmr.12282","article-title":"Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151","volume":"27","author":"Gallagher","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jid.2020.12.038_bib14","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/jid.2014.243","article-title":"The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells","volume":"134","author":"Gallagher","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.12.038_bib15","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jid.2020.12.038_bib16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jid.2020.12.038_bib17","doi-asserted-by":"crossref","first-page":"21507","DOI":"10.18632\/oncotarget.4242","article-title":"Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling","volume":"6","author":"Heinemann","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jid.2020.12.038_bib18","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1016\/j.celrep.2017.11.095","article-title":"BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer","volume":"21","author":"Karakashev","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.jid.2020.12.038_bib19","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.3389\/fimmu.2019.02293","article-title":"WNT\/\u03b2-catenin signaling pathway regulating T cell-inflammation in the tumor microenvironment","volume":"10","author":"Li","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2020.12.038_bib20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fonc.2019.00268","article-title":"Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies","volume":"9","author":"Luebker","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jid.2020.12.038_bib21","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jid.2020.12.038_bib22","first-page":"1429","article-title":"Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long-term BRAF inhibition","volume":"56","author":"Madorsky Rowdo","year":"2020","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jid.2020.12.038_bib23","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/nature09589","article-title":"Suppression of inflammation by a synthetic histone mimic","volume":"468","author":"Nicodeme","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jid.2020.12.038_bib24","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.aao1710","article-title":"A\u00a0major chromatin regulator determines resistance of tumor cells to T cell-mediated killing","volume":"359","author":"Pan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jid.2020.12.038_bib25","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/cam4.667","article-title":"BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma","volume":"5","author":"Paoluzzi","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.jid.2020.12.038_bib26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10637-018-0661-2","article-title":"CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia","volume":"37","author":"Rahaman","year":"2019","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.jid.2020.12.038_bib27","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jid.2020.12.038_bib28","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2020.12.038_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/15592294.2014.1003746","article-title":"Epigenetic regulation in human melanoma: past and future","volume":"10","author":"Sarkar","year":"2015","journal-title":"Epigenetics"},{"key":"10.1016\/j.jid.2020.12.038_bib30","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/j.bmcl.2012.02.041","article-title":"Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A)","volume":"22","author":"Seal","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jid.2020.12.038_bib31","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.1158\/0008-5472.CAN-13-0122-T","article-title":"BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy","volume":"73","author":"Segura","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2020.12.038_bib32","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jid.2020.12.038_bib33","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","article-title":"The mechanisms behind the therapeutic activity of BET bromodomain inhibition","volume":"54","author":"Shi","year":"2014","journal-title":"Mol Cell"},{"key":"10.1016\/j.jid.2020.12.038_bib34","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-17-0401","article-title":"Recurrent tumor cell-intrinsic and -Extrinsic alterations during MAPKi-induced melanoma regression and early adaptation","volume":"7","author":"Song","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jid.2020.12.038_bib35","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.7150\/thno.36218","article-title":"The \"ART\" of Epigenetics in Melanoma: from histone \"Alterations, to Resistance and Therapies\"","volume":"10","author":"Strub","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jid.2020.12.038_bib36","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1038\/s41467-018-05966-z","article-title":"SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling","volume":"9","author":"Strub","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2020.12.038_bib37","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1016\/j.jid.2020.02.042","article-title":"EZH2 cooperates with DNA methylation to downregulate key tumour suppressors and interferon gene signatures in melanoma","volume":"140","author":"Tiffen","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.12.038_bib38","doi-asserted-by":"crossref","first-page":"27023","DOI":"10.18632\/oncotarget.4809","article-title":"Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes","volume":"6","author":"Tiffen","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jid.2020.12.038_bib39","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1002\/ijc.33000","article-title":"Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma","volume":"147","author":"Tseng","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jid.2020.12.038_bib40","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1093\/bioinformatics\/btv313","article-title":"DSigDB: drug signatures database for gene set analysis","volume":"31","author":"Yoo","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jid.2020.12.038_bib41","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.cell.2018.09.051","article-title":"Targeting CDK9 reactivates epigenetically silenced genes in cancer","volume":"175","author":"Zhang","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jid.2020.12.038_bib42","doi-asserted-by":"crossref","first-page":"8206","DOI":"10.18632\/oncotarget.23654","article-title":"Distinct histone modifications denote early stress-induced drug tolerance in cancer","volume":"9","author":"Al Emran","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jid.2020.12.038_bib43","doi-asserted-by":"crossref","first-page":"21507","DOI":"10.18632\/oncotarget.4242","article-title":"Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling","volume":"6","author":"Heinemann","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jid.2020.12.038_bib44","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10637-018-0661-2","article-title":"CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia","volume":"37","author":"Rahaman","year":"2019","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.jid.2020.12.038_bib45","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1016\/j.jid.2020.02.042","article-title":"EZH2 cooperates with DNA methylation to downregulate key tumour suppressors and interferon gene signatures in melanoma","volume":"140","author":"Tiffen","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.12.038_bib46","doi-asserted-by":"crossref","first-page":"27023","DOI":"10.18632\/oncotarget.4809","article-title":"Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes","volume":"6","author":"Tiffen","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jid.2020.12.038_bib47","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1002\/ijc.33000","article-title":"Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma","volume":"147","author":"Tseng","year":"2020","journal-title":"Int J Cancer"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21011210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21011210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:22:01Z","timestamp":1758302521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X21011210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0022202X21011210"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2020.12.038","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2020.12.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}